Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux Disease

Inclusion Criteria: * Subjects who have experienced both heartburn and acid regurgitation * Subjects in whom no mucosal breaks were observed on upper GI endoscopy at Visit 1 by LA Classification * Subjects who fully understand this clinical trial and voluntarily signed the informed consent form Exclusion Criteria: * Subjects who have significant gastrointestinal diseases or procedures affecting the esophagus, stomach, or duodenum * Subjects who have a history of recent substance abuse, malignancy, systemic autoimmune or immune deficiency diseases, refractory response to PPI/P-CAB, hypersensitivity to study drugs, genetic metabolic disorders, or significant psychiatric conditions. * Subjects who showed clinically significant abnormalities in laboratory tests * Positive result in the H. pylori test * Pregnant or breast-feeding women * Subjects who require hospitalization are scheduled to undergo surgery during the study period, or have undergone major surgery requiring general anesthesia * Other people deemed unsuitable for participation in this study according to the medical opinion of the investigator